Poor medical adherence attributed to patient compliance has impacted the medical community, at times, in a deleterious fashion. To combat this, the medical community has attempted to provide therapeutics in the form of absorption enhancing techniques. To improve the absorption rate techniques such as drug encapsulation using proteins, liposomes, or nanotransfersomes have been developed using mass spectrometry. These techniques, have aided in the enhanced absorption of analytes with low bioavailability, including curcumin, simvastatin, and lysozyme. Specifically, mass spectrometry allows for the development and monitoring of nanotransfersome encapsulated analytes and the permeation across the dermal membrane. This transdermal delivery would eliminate the problems encountered during first pass metabolism, while allowing for higher concentrations of analyte to be maintained in the blood serum. This can be coupled to a thermosensitive gelatin that provides for a dose control mechanism to be accomplished, allowing multiple doses to be delivered using one transdermal patch system. The novel delivery system developed using mass spectrometry, allows the analyte to be delivered into the circulatory system at a controlled dosage, via transdermal absorption. This system will aid in eliminating problems associated with patient compliance, as the patient is no longer reliant on memory to self-dose. Further, this system mitigates the concerns of patients overdosing with more potent pharmaceuticals.